Private EquityRIA · CRD 282721Exempt Reporting AdviserPrivate Fund Adviser

Updated:

InvestEco Capital

InvestEco's investment focus is high growth North American companies that promote health and sustainability in the food & agricultural sector.

InvestEco Capital logo

InvestEco Capital

InvestEco's investment focus is high growth North American companies that promote health and sustainability in the food & agricultural sector. They seek to deliver strong financial returns to investors while helping portfolio companies build a better world.

General information

Firm type

Private Equity

Year founded

2002

Location

Region

North America

Country

Canada

City

Toronto

Corporate office

Toronto, ON, Canada

Principals

Andrew Heintzman

President & CEO

Sector focus

AgriTech & FoodTechEnergy Transition & Renewables

Frequently asked questions

Who runs investment decisions at InvestEco Capital?

President and CEO Andrew Heintzman leads the investment team and sets the firm's strategic direction. InvestEco operates with a lean partnership model, where senior investment professionals share deal-sourcing and portfolio-oversight responsibilities. The firm has historically relied on a tight circle of partners and operating advisors rather than a large hierarchical investment committee.

How does InvestEco Capital source proprietary deal flow?

InvestEco's sourcing relies on the firm's deep network within North American organic and natural-food supply chains, built over more than two decades. The firm often encounters companies before formal sale processes begin, through relationships with independent brands, distributors, and agricultural input providers. This long-tenured ecosystem access is the closest thing to proprietary deal flow in a sector where many growth-stage brands are publicly known.

Which sectors does InvestEco Capital explicitly avoid?

InvestEco's mandate excludes conventional industrial agriculture, fossil-fuel-derived inputs, and any food business with a net-negative environmental footprint that cannot be meaningfully improved through operational change. The firm also does not invest in therapeutics, pharma, or medical-technology companies, even where they overlap with nutrition science.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Toronto Private Equity profiles